167 related articles for article (PubMed ID: 36238289)
1. The immune microenvironment landscape shows treatment-specific differences in rectal cancer patients.
Graham Martínez C; Barella Y; Kus Öztürk S; Ansems M; Gorris MAJ; van Vliet S; Marijnen CAM; Nagtegaal ID
Front Immunol; 2022; 13():1011498. PubMed ID: 36238289
[TBL] [Abstract][Full Text] [Related]
2. The Effects of Neoadjuvant Treatment on the Tumor Microenvironment in Rectal Cancer: Implications for Immune Activation and Therapy Response.
Chen CC; Wu ML; Huang KC; Huang IP; Chung YL
Clin Colorectal Cancer; 2020 Dec; 19(4):e164-e180. PubMed ID: 32387305
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive evaluation of the tumor immune microenvironment and its dynamic changes in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy: From the phase II ADORE study.
Cho H; Kim JE; Hong YS; Kim SY; Kim J; Ryu YM; Kim SY; Kim TW
Oncoimmunology; 2022; 11(1):2148374. PubMed ID: 36451674
[TBL] [Abstract][Full Text] [Related]
4. Impact of adjuvant chemotherapy after neoadjuvant radio- or radiochemotherapy for patients with locally advanced rectal cancer.
Lichthardt S; Zenorini L; Wagner J; Baur J; Kerscher A; Matthes N; Kastner C; Pelz J; Kunzmann V; Germer CT; Wiegering A
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2363-2373. PubMed ID: 28756493
[TBL] [Abstract][Full Text] [Related]
5. Relationship between stromal regulatory T cells and the response to neoadjuvant chemotherapy for locally advanced rectal cancer.
Sekizawa K; Nakagawa K; Ichikawa Y; Suwa H; Ozawa M; Momiyama M; Ishibe A; Watanabe J; Ota M; Kato I; Endo I
Surg Today; 2022 Feb; 52(2):198-206. PubMed ID: 34081199
[TBL] [Abstract][Full Text] [Related]
6. Tumor Microenvironment Mediators CD8
Zaghloul H; Abbas A; Abdulah D
J Gastrointest Cancer; 2021 Mar; 52(1):177-186. PubMed ID: 32112202
[TBL] [Abstract][Full Text] [Related]
7. Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer.
McCoy MJ; Hemmings C; Miller TJ; Austin SJ; Bulsara MK; Zeps N; Nowak AK; Lake RA; Platell CF
Br J Cancer; 2015 Dec; 113(12):1677-86. PubMed ID: 26645238
[TBL] [Abstract][Full Text] [Related]
8. [Effects of neoadjuvant chemoradiotherapy on infiltrating immune cells in the tumor microenvironment of rectal cancer].
Yang Q; Zhou C; Han C; Zhang Y; Jiang Y; Li Z; Ma J
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Aug; 41(8):1270-1276. PubMed ID: 34549721
[TBL] [Abstract][Full Text] [Related]
9. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Chemotherapy Seemed Not to Have Survival Benefit in Rectal Cancer Patients with ypTis-2N0 After Preoperative Radiotherapy and Surgery from a Population-Based Propensity Score Analysis.
Hu X; Li YQ; Li QG; Ma YL; Peng JJ; Cai SJ
Oncologist; 2019 Jun; 24(6):803-811. PubMed ID: 29674444
[TBL] [Abstract][Full Text] [Related]
11. Preoperative neo-adjuvant therapy for curable rectal cancer--reaching a consensus 2008.
Scott NA; Susnerwala S; Gollins S; Myint AS; Levine E
Colorectal Dis; 2009 Mar; 11(3):245-8. PubMed ID: 18637934
[TBL] [Abstract][Full Text] [Related]
12. [Controversies and progress in adjuvant chemotherapy for patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy].
Li XX; Li QG
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):594-596. PubMed ID: 31238639
[TBL] [Abstract][Full Text] [Related]
13. Management of the adenocarcinoma of the upper rectum: a reappraisal.
Pechlivanides G; Gourtsoyianni S; Gouvas N; Sougklakos J; Xynos E
Updates Surg; 2021 Apr; 73(2):513-526. PubMed ID: 33108641
[TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
[TBL] [Abstract][Full Text] [Related]
16. Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications.
Schiffmann L; Wedermann N; Gock M; Prall F; Klautke G; Fietkau R; Rau B; Klar E
BMC Surg; 2013 Sep; 13():43. PubMed ID: 24073705
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of rectal cancer patients improves with downstaging by intensified neoadjuvant radiochemotherapy - a matched pair analysis.
Schiffmann L; Klautke G; Wedermann N; Gock M; Prall F; Fietkau R; Rau B; Klar E
BMC Cancer; 2013 Aug; 13():388. PubMed ID: 23947828
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom?
De Stefano A; Moretto R; Bucci L; Pepe S; Romano FJ; Cella AC; Attademo L; Rosanova M; De Falco S; Fiore G; Raimondo L; De Placido S; Carlomagno C
Clin Colorectal Cancer; 2014 Sep; 13(3):185-91. PubMed ID: 25080847
[TBL] [Abstract][Full Text] [Related]
19. The local immune phenotype influences prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation.
Schollbach J; Kircher S; Wiegering A; Anger F; Rosenwald A; Germer CT; Löb S
Int J Colorectal Dis; 2020 Feb; 35(2):365-370. PubMed ID: 31828368
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Chemotherapy Is Associated With Improved Overall Survival in Locally Advanced Rectal Cancer After Achievement of a Pathologic Complete Response to Chemoradiation.
Shahab D; Gabriel E; Attwood K; Ma WW; Francescutti V; Nurkin S; Boland PM
Clin Colorectal Cancer; 2017 Dec; 16(4):300-307. PubMed ID: 28420585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
